A study protocol evaluating the effectiveness of the older adult's digital health literacy (ODDHeaL) intervention.

PLoS OneSep 28, 2026 (epub)
Clinical ResearchGeriatricsPreventive Medicine / Public Health

Nor Hazimah Rosle, Halimatus Sakdiah Minhat, Lim Poh Ying et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluates the effectiveness of the Older Adults Digital Health Literacy (ODDHeaL) intervention in improving digital health literacy among community-dwelling adults aged 55 and older. The study includes participants who own smartphones and have normal M-ECAQ and Katz ADL scores. The intervention aims to enhance health literacy, self-efficacy, and health information-seeking behavior, with assessments conducted at baseline, immediately post-intervention, and two months later.

Key findings

  • The ODDHeaL intervention is designed to improve digital health literacy among older adults.
  • Participants will be evaluated at baseline, immediately after, and two months post-intervention.
  • The study employs an intention-to-treat analysis approach.

Why it matters

Improving digital health literacy in older adults is crucial for enhancing their ability to manage health conditions and engage actively in their healthcare, especially in a technology-driven environment.

Source

PubMed · PMID 42804489

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.